Monopar Therapeutics Inc MNPR
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if MNPR is a good fit for your portfolio.
News
-
Monopar Announces Radiopharma Presentation Selected for Society of Nuclear Medicine and Molecular Imaging 2024 Annual Meeting
-
Monopar Announces Filing of Patent Protecting MNPR-101 Radiopharma Optimization Findings
-
Monopar Initiates Radiopharma Phase 1 Clinical Trial for MNPR-101-Zr in Advanced Cancer Patients
-
Monopar Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Developments
-
Monopar Announces Positive Preclinical Therapeutic Isotope Data for its MNPR-101 Radiopharma Program
-
Thinking about buying stock in Monopar Therapeutics, Aquestive Therapeutics, NXU, SeaStar Medical, or TDCX?
-
Thinking about buying stock in Monopar Therapeutics, AMC Entertainment, Zyversa Therapeutics, MoneyHero, or Blink Charging?
-
Monopar Provides Update on MNPR-101-Zr Radiopharma Clinical Trial
Trading Information
- Previous Close Price
- $0.65
- Day Range
- $0.63–0.68
- 52-Week Range
- $0.27–1.75
- Bid/Ask
- $0.63 / $0.67
- Market Cap
- $11.47 Mil
- Volume/Avg
- 39,446 / 6.0 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicin for the treatment of soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 12
- Website
- https://www.monopartx.com
Valuation
|
Metric
|
MNPR
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 1.75 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
MNPR
|
|---|---|
Quick Ratio | 4.13 |
Current Ratio | 4.17 |
Interest Coverage | — |
Quick Ratio
MNPR
Profitability
|
Metric
|
MNPR
|
|---|---|
Return on Assets (Normalized) | −63.35% |
Return on Equity (Normalized) | −83.24% |
Return on Invested Capital (Normalized) | −88.71% |
Return on Assets
MNPR
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Vbnzdqmyf | Ygc | $562.4 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Hrprcnjby | Pzqgnb | $103.6 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Pcbcnbhpl | Wxmwxj | $99.5 Bil | |
MRNA
| Moderna Inc | Qjctnbnc | Xcbb | $38.8 Bil | |
ARGX
| argenx SE ADR | Qpctsszn | Cxfl | $21.4 Bil | |
BNTX
| BioNTech SE ADR | Vxtptdhj | Fln | $21.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Jcjkkhlb | Wbdmdw | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Zgcvddpd | Qclvmr | $17.3 Bil | |
RPRX
| Royalty Pharma PLC Class A | Zzksvkrm | Lxrsq | $12.5 Bil | |
INCY
| Incyte Corp | Cllgyzmmy | Mxgkmw | $11.6 Bil |